Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
22:51
Luca Niculescu asks the state to tighten its belt before introducing new taxes
22:34
Minister of Development, Alexandru Stoica, clarifies the rules for enclosed balconies without a permit: the double tax does not apply
22:19
Luca Niculescu announces that Romania has practically completed the OECD accession process, with benefits for investment and jobs
22:02
Prime Minister Luca Niculescu confirms pension increases in 2027: “There will be an increase”
21:45
Traian Băsescu criticizes Romania’s policy toward the USA: “We have not had any policy toward the United States in recent years, since 2004. We have only had the policy of a fool”
See more news